-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Aquestive Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2017 to 2023.
- Aquestive Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$2.75M, a 52.6% increase year-over-year.
- Aquestive Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$25.7M, a 13.7% decline year-over-year.
- Aquestive Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$7.87M, a 85.5% increase from 2022.
- Aquestive Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$54.4M, a 22.9% increase from 2021.
- Aquestive Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$70.5M, a 26.5% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)